179 related articles for article (PubMed ID: 37533228)
1. Genomic alterations of oligodendrogliomas at distant recurrence.
Liu G; Bu C; Guo G; Zhang Z; Sheng Z; Deng K; Wu S; Xu S; Bu Y; Gao Y; Wang M; Liu G; Kong L; Li T; Li M; Bu X
Cancer Med; 2023 Aug; 12(16):17171-17183. PubMed ID: 37533228
[TBL] [Abstract][Full Text] [Related]
2. Genetic and epigenetic stability of oligodendrogliomas at recurrence.
Aihara K; Mukasa A; Nagae G; Nomura M; Yamamoto S; Ueda H; Tatsuno K; Shibahara J; Takahashi M; Momose T; Tanaka S; Takayanagi S; Yanagisawa S; Nejo T; Takahashi S; Omata M; Otani R; Saito K; Narita Y; Nagane M; Nishikawa R; Ueki K; Aburatani H; Saito N
Acta Neuropathol Commun; 2017 Mar; 5(1):18. PubMed ID: 28270234
[TBL] [Abstract][Full Text] [Related]
3. Molecular background of oligodendroglioma: 1p/19q, IDH, TERT, CIC and FUBP1.
Cahill DP; Louis DN; Cairncross JG
CNS Oncol; 2015; 4(5):287-94. PubMed ID: 26545048
[TBL] [Abstract][Full Text] [Related]
4. Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers.
Yip S; Butterfield YS; Morozova O; Chittaranjan S; Blough MD; An J; Birol I; Chesnelong C; Chiu R; Chuah E; Corbett R; Docking R; Firme M; Hirst M; Jackman S; Karsan A; Li H; Louis DN; Maslova A; Moore R; Moradian A; Mungall KL; Perizzolo M; Qian J; Roldan G; Smith EE; Tamura-Wells J; Thiessen N; Varhol R; Weiss S; Wu W; Young S; Zhao Y; Mungall AJ; Jones SJ; Morin GB; Chan JA; Cairncross JG; Marra MA
J Pathol; 2012 Jan; 226(1):7-16. PubMed ID: 22072542
[TBL] [Abstract][Full Text] [Related]
5. ETV/Pea3 family transcription factor-encoding genes are overexpressed in CIC-mutant oligodendrogliomas.
Padul V; Epari S; Moiyadi A; Shetty P; Shirsat NV
Genes Chromosomes Cancer; 2015 Dec; 54(12):725-33. PubMed ID: 26357005
[TBL] [Abstract][Full Text] [Related]
6. PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial Tumors.
Tateishi K; Nakamura T; Juratli TA; Williams EA; Matsushita Y; Miyake S; Nishi M; Miller JJ; Tummala SS; Fink AL; Lelic N; Koerner MVA; Miyake Y; Sasame J; Fujimoto K; Tanaka T; Minamimoto R; Matsunaga S; Mukaihara S; Shuto T; Taguchi H; Udaka N; Murata H; Ryo A; Yamanaka S; Curry WT; Dias-Santagata D; Yamamoto T; Ichimura K; Batchelor TT; Chi AS; Iafrate AJ; Wakimoto H; Cahill DP
Clin Cancer Res; 2019 Jul; 25(14):4375-4387. PubMed ID: 30975663
[TBL] [Abstract][Full Text] [Related]
7. IDH-Mutant Astrocytoma With Chromosome 19q13 Deletion Manifesting as an Oligodendroglioma-Like Morphology.
Miyake Y; Fujii K; Nakamaura T; Ikegaya N; Matsushita Y; Gobayashi Y; Iwashita H; Udaka N; Kumagai J; Murata H; Takemoto Y; Yamanaka S; Ichimura K; Tateishi K; Yamamoto T
J Neuropathol Exp Neurol; 2021 Feb; 80(3):247-253. PubMed ID: 33432322
[TBL] [Abstract][Full Text] [Related]
8. Gliosarcoma arising from oligodendroglioma, IDH mutant and 1p/19q codeleted.
Yasuda T; Nitta M; Komori T; Kobayashi T; Masui K; Maruyama T; Sawada T; Muragaki Y; Kawamata T
Neuropathology; 2018 Feb; 38(1):41-46. PubMed ID: 28812310
[TBL] [Abstract][Full Text] [Related]
9. Loss of CIC and FUBP1 expressions are potential markers of shorter time to recurrence in oligodendroglial tumors.
Chan AK; Pang JC; Chung NY; Li KK; Poon WS; Chan DT; Shi Z; Chen L; Zhou L; Ng HK
Mod Pathol; 2014 Mar; 27(3):332-42. PubMed ID: 24030748
[TBL] [Abstract][Full Text] [Related]
10. Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma.
Thomas AA; Abrey LE; Terziev R; Raizer J; Martinez NL; Forsyth P; Paleologos N; Matasar M; Sauter CS; Moskowitz C; Nimer SD; DeAngelis LM; Kaley T; Grimm S; Louis DN; Cairncross JG; Panageas KS; Briggs S; Faivre G; Mohile NA; Mehta J; Jonsson P; Chakravarty D; Gao J; Schultz N; Brennan CW; Huse JT; Omuro A
Neuro Oncol; 2017 Oct; 19(10):1380-1390. PubMed ID: 28472509
[TBL] [Abstract][Full Text] [Related]
11. Comparative molecular analysis of primary and recurrent oligodendroglioma that acquired imbalanced 1p/19q codeletion and TP53 mutation: a case report.
Ono T; Reinhardt A; Takahashi M; Nanjo H; Kamataki A; von Deimling A; Shimizu H
Acta Neurochir (Wien); 2020 Dec; 162(12):3019-3024. PubMed ID: 32785787
[TBL] [Abstract][Full Text] [Related]
12. Pattern of failure in anaplastic glioma patients with an IDH1/2 mutation.
Back M; Jayamanne D; Brazier D; Newey A; Bailey D; Schembri G; Hsiao E; Khasraw M; Wong M; Kastelan M; Brown C; Wheeler H
Strahlenther Onkol; 2020 Jan; 196(1):31-39. PubMed ID: 31028406
[TBL] [Abstract][Full Text] [Related]
13. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group.
van den Bent MJ; Dubbink HJ; Marie Y; Brandes AA; Taphoorn MJ; Wesseling P; Frenay M; Tijssen CC; Lacombe D; Idbaih A; van Marion R; Kros JM; Dinjens WN; Gorlia T; Sanson M
Clin Cancer Res; 2010 Mar; 16(5):1597-604. PubMed ID: 20160062
[TBL] [Abstract][Full Text] [Related]
14. Clinical and histological characteristics of recurrent oligodendroglial tumors: comparison between primary and recurrent tumors in 18 cases.
Kanamori M; Kumabe T; Shibahara I; Saito R; Yamashita Y; Sonoda Y; Suzuki H; Watanabe M; Tominaga T
Brain Tumor Pathol; 2013 Jul; 30(3):151-9. PubMed ID: 23053495
[TBL] [Abstract][Full Text] [Related]
15. Oligodendrogliomas: new insights from the genetics and perspectives.
Alentorn A; Sanson M; Idbaih A
Curr Opin Oncol; 2012 Nov; 24(6):687-93. PubMed ID: 22913971
[TBL] [Abstract][Full Text] [Related]
16. Molecular and clonal evolution
Liu G; Bu C; Guo G; Zhang Z; Sheng Z; Deng K; Wu S; Xu S; Bu Y; Gao Y; Wang M; Liu G; Kong L; Li T; Li M; Bu X
iScience; 2023 Sep; 26(9):107528. PubMed ID: 37649695
[TBL] [Abstract][Full Text] [Related]
17. Utility of targeted next-generation sequencing assay to detect 1p/19q co-deletion in formalin-fixed paraffin-embedded glioma specimens.
Pallavajjala A; Haley L; Stinnett V; Adams E; Pallavajjala R; Huang J; Morsberger L; Hardy M; Long P; Gocke CD; Eshleman JR; Rodriguez FJ; Zou YS
Hum Pathol; 2022 Aug; 126():63-76. PubMed ID: 35561840
[TBL] [Abstract][Full Text] [Related]
18. Characterizing temporal genomic heterogeneity in pediatric high-grade gliomas.
Salloum R; McConechy MK; Mikael LG; Fuller C; Drissi R; DeWire M; Nikbakht H; De Jay N; Yang X; Boue D; Chow LML; Finlay JL; Gayden T; Karamchandani J; Hummel TR; Olshefski R; Osorio DS; Stevenson C; Kleinman CL; Majewski J; Fouladi M; Jabado N
Acta Neuropathol Commun; 2017 Oct; 5(1):78. PubMed ID: 29084603
[TBL] [Abstract][Full Text] [Related]
19. CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas.
Sahm F; Koelsche C; Meyer J; Pusch S; Lindenberg K; Mueller W; Herold-Mende C; von Deimling A; Hartmann C
Acta Neuropathol; 2012 Jun; 123(6):853-60. PubMed ID: 22588899
[TBL] [Abstract][Full Text] [Related]
20. Characterizing temporal genomic heterogeneity in pediatric low-grade gliomas.
Lazow MA; Hoffman L; Schafer A; Osorio DS; Boué DR; Rush S; Wright E; Lane A; DeWire-Schottmiller MD; Smolarek T; Sipple J; Taggert H; Reuss J; Salloum R; Hummel TR; de Blank P; Pillay-Smiley N; Sutton ME; Asher A; Stevenson CB; Drissi R; Finlay JL; Fouladi M; Fuller C
Acta Neuropathol Commun; 2020 Nov; 8(1):182. PubMed ID: 33153497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]